Novartis AG ADR (NVS)vsSo-Young International Inc (SY)
NVS
Novartis AG ADR
$160.32
-0.04%
HEALTHCARE · Cap: $303.67B
SY
So-Young International Inc
$1.94
-8.06%
HEALTHCARE · Cap: $206.26M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 3358% more annual revenue ($57.36B vs $1.66B). NVS leads profitability with a 17.5% profit margin vs -15.6%. NVS earns a higher WallStSmart Score of 48/100 (D+).
NVS
Hold48
out of 100
Grade: D+
SY
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.8%
Fair Value
$95.76
Current Price
$160.32
$64.56 premium
Intrinsic value data unavailable for SY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 34.3%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Reasonable price relative to book value
Revenue surging 45.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
Smaller company, higher risk/reward
ROE of -17.2% — below average capital efficiency
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : SY
The strongest argument for SY centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 45.6% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : SY
The primary concerns for SY are Market Cap, Return on Equity, Altman Z-Score.
Key Dynamics to Monitor
NVS profiles as a value stock while SY is a hypergrowth play — different risk/reward profiles.
SY carries more volatility with a beta of 2.20 — expect wider price swings.
SY is growing revenue faster at 45.6% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (48/100 vs 44/100), backed by strong 17.5% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →So-Young International Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · China
So-Young International Inc. operates an online platform for consumer health and medical aesthetic services that focuses on discretionary medical treatments.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?